touchINFECTIOUSDISEASES were pleased to meet with Timothy Hinks (Nuffield Department of Medicine, University of Oxford, Oxford, UK) to discuss the results of the ATOMIC2 study results, investigating azithromycin in the treatment of COVID-19.
The abstract entitled: ‘A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19: the ATOMIC2 trial’ was presented at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), and the full paper is to be published in The Lancet Respiratory Medicine.
Questions:
- What has the existing evidence taught us about the effectiveness of azithromycin in treating COVID-19? (0:09)
- What were the unique features of the ATOMIC2 study compared to existing studies? (1:32)
- What were the efficacy and safety findings in the study? (2:46)
- Why do you think that the addition of azithromycin to standard care failed to reduce hospitalisation, respiratory failure, or death in COVID-19 patients? (3:40)
- Is there a future role of azithromycin in the therapeutic paradigm for COVID-19? (4:37)
Disclosures: Timothy Hinks has received grants from Pfizer Inc., grants from University of Oxford, grants from the Wellcome Trust, grants from The Guardians of the Beit Fellowship, and grants from the NIHR Oxford Biomedical Research Centre during the conduct of the study; and personal fees from Astra Zeneca, personal fees from TEVA, personal fees from Peer Voice outside the submitted work.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed in coverage of the 31st ECCMID Congress 2021.
